Every earnings call for TORNTPHARM — management tone, guidance, KPIs and promise tracking, quarter by quarter.
TORNTPHARM · 5 transcripts · Healthcare · latest Q3 FY26Revenue ₹3,303 cr (+18% YoY); Operating EBITDA ₹1,088 cr (+19% YoY); EBITDA Margin 32.9%. Revenue reached ₹3,303 crores, representing an 18% YoY growth.
Read full transcript & analysisRevenue ₹3,302 cr (+14% YoY); Operating EBITDA ₹1,083 cr (+15% YoY); EBITDA Margin 32.8%. Revenue reached ₹3,302 crores, representing a 14% YoY growth.
Read full transcript & analysisRevenue ₹3,178 cr (+11% YoY); Operating EBITDA ₹1,032 cr (+14% YoY); Adjusted EBITDA Margin 32.9%. Revenue reached ₹3,178 crores, representing an 11% YoY growth.
Read full transcript & analysisRevenue ₹2,809 cr (+3% YoY); Operating EBITDA ₹914 cr (+5% YoY); EBITDA Margin 32.5%. Revenue of ₹2,809 crores, up 3% YoY; underlying growth normalized for insulin and currency is 7%.
Read full transcript & analysisRevenue ₹2,889 cr (+9% YoY); Operating EBITDA ₹939 cr (+14% YoY); EBITDA Margin 32.5%. Revenue reached ₹2,889 crores, representing a 9% YoY growth.
Read full transcript & analysis